{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2769184","value":"0.0516596"},{"groupId":"OG001","spread":"0.3366162","value":"0.0068695"},{"groupId":"OG002","spread":"0.1839149","value":"0.1267145"},{"groupId":"OG003","spread":"0.2844673","value":"0.0480281"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"69"}],"units":"Participants"}],"description":"The AQoL is a multi-attribute utility health-related quality of life (HRQoL) instrument. It combines the 4 dimensions of independent living, relationships, senses and mental health into a single utility score. The AQoL instrument scores between 1 (best HRQoL) and -0.04 (worst possible HRQoL).","dispersionType":"Standard Deviation","groups":[{"description":"Participants without 1q21 amplification. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG000","title":"1q21 Not Amplified"},{"description":"Participants with 1q21 amplification. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG001","title":"1q21 Amplified"},{"description":"Participants who failed 1q21 test/had missing results for 1q21 test. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG002","title":"Failed/Missing"},{"description":"Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG003","title":"Total"}],"paramType":"MEAN","populationDescription":"Intent-to-treat (ITT) population - All participants who were screened and received at least one dose of PAD","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Assessment of Quality of Life (AQoL) Scores","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}